1. TACTICS-HF
Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48 hours (n = 129) versus placebo (n = 128).
Results
(p = 0.32)
% responders at 24 hours (moderate or marked improvement and no need for rescue therapy or death): 16% with tolvaptan versus 20% with placebo (p = 0.32)
Mean fluid loss at 24 hours: 2182 cc with tolvaptan versus 1541 cc with placebo (p = 0.006) % 20 16
Conclusions
Among patients hospitalized with acute heart failure and treated with standard intravenous diuretic therapy, the addition of tolvaptan versus placebo did not improve dyspnea symptoms
Tolvaptan
Placebo
Felker GM, et al. J Am Coll Cardiol 2016;Sep 18:[Epub]